Cybin (HELP) H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference summary

Conference highlights

• Over 20 companies presented at the fifth annual H.C. Wainwright Virtual Neuro Perspectives Conference, with a focus on neurology and novel CNS drug delivery methods.

• Panels and fireside chats covered a range of indications including depression, epilepsy, Alzheimer's disease, and ALS.

Company overview and differentiation

• Founded pre-COVID, the company grew virtually, went public in 2020, and made two acquisitions, resulting in an extensive IP portfolio with over 50 granted patents and 180 pending.

• Focuses on modified psychoactive compounds, specifically a psilocybin analog (CYB003) and deuterated DMT (CYB004), both protected as new chemical entities.

CYB003 program for major depressive disorder (MDD)

• CYB003, a deuterated psilocybin analog, is being developed as adjunctive therapy for MDD, targeting rapid and durable symptom reduction.

• Phase II data showed rapid onset (15 minutes), large and sustained reduction in depressive symptoms, and 75% response and remission rates after two doses, sustained for four months.

• Phase III program, aligned with FDA, includes two short-term studies (total 550 patients) and a 12-month extension, using independent, remote blinded raters and a three-arm design to address unblinding and bias.

• Adjunctive positioning allows immediate dosing without discontinuing background medications, addressing a broad MDD population.